ASP 4178
Alternative Names: ASP4178Latest Information Update: 05 Nov 2023
Price :
$50 *
At a glance
- Originator Astellas Pharma
- Class Antihyperglycaemics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 01 Feb 2012 ASP 4178 is available for licensing as of 01 Feb 2012. http://www.astellas.com
- 01 Feb 2012 Discontinued - Phase-I for Type-2 diabetes mellitus in USA (PO)
- 01 Aug 2011 Phase I development in Type-2 diabetes mellitus is ongoing in USA